$TSOI beautiful News out Therapeutic Solutions Int
Post# of 12925
(Total Views: 57)
Posted On: 07/08/2019 10:01:42 AM
$TSOI beautiful News out Therapeutic Solutions International Develops Glucoraphanin + NanoStilbene Encapsulated product for reduction of Prostate Specific Antigen (PSA)
OCEANSIDE, Calif., July 08, 2019 (GLOBE NEWSWIRE) -- via NetworkWire -- Therapeutic Solutions International, Inc., (OTC Markets: TSOI) announced today the development of a broccoli sprout extract containing the precursor glucoraphanin in a combined 200mg dose of NanoStilbene.
As previously announced, the same NanoStilbene that was administered to 12 patients with advanced solid cancers for three weeks is the base for this new product we are calling "NanoPSA." Daily treatment with 300mg of NanoStilbene caused reduction in serum levels of inflammatory markers TNF-alpha, IL-6, and CRP [1]. Additionally, NK cytotoxicity was augmented, suggesting that NanoStilbene may be a useful adjuvant to immunotherapy of cancer rescuing T-cell and NK cell activities. These same inflammatory molecules are involved in elevated levels of PSA.
Glucoraphanin, found primarily in broccoli, is another potent antioxidant like pterostilbene. The main purpose of antioxidants is to protect the cells in our body from damage caused by oxidative stress, namely free radicals, which are unstable compounds missing an electron. This free radical damage is also closely linked with inflammation because the body recognizes oxidative damage as a threat.
We know what the result is, a damaging cycle of oxidation: damage – immune cells – more damage. Increasing antioxidant potential in the body provides a solution by helping to prevent a lot of the oxidative damage in the first place.
Glucoraphanin, as we have produced it, is a precursor to our end product, which is another compound called sulforaphane. Glucoraphanin belongs to a category of compounds called glucosinolates which are naturally found in cruciferous vegetables. Glucosinolates are enzymatically converted into isothiocyanates, which are active in the body. This enzymatic conversion is performed by myrosinase, which is also found naturally in cruciferous vegetables. Myrosinase-like activity also occurs in our intestinal microflora, so if glucoraphanin is consumed by itself, our gut microflora will convert a portion of it to sulforaphane, a compound within the isothiocyanate group of organosulfur compounds.
"This is an extremely exciting development in our research with our end target compound being sulforaphane. Sulforaphane has been shown to significantly reduce PSA after 20 weeks of consuming broccoli sprout extract (BSE). There is little misunderstanding that inflammation causes gut dysbiosis, and since we are depending upon the microflora to hydrolyze the glucoraphanin into sulforaphane, it seems perfectly reasonable to want the gut in the best shape it can be in. We already know pterostilbene supplementation causes beneficial changes in microbiota composition, improved metabolic function, strengthened insulin sensitivity and induced anti-obesity effects and so we have blended the two into a single formulation, providing a clinically relevant amount of both actives. Our mission is to either up-regulate or down-regulate the immune system, and NanoPSA is another tool in the box to achieve our mission," said Timothy Dixon, president and CEO of Therapeutic Solutions International. "We hope to have this product available, which will come in capsule form, on the shelf very quickly."
[1] https://mynanostilbene.com/?page_id=137
About Therapeutic Solutions International, Inc. Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. Immune modulation refers to the ability to upregulate (make more active) or downregulate (make less active) one's immune system. The Company's corporate website is www.therapeuticsolutionsint.com and e-commerce at www.youcanordernow.com.
Safe Harbor Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our SEC filings. To the extent that statements in this press release are not strictly historical, including statements as to product launch timing, revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future collaboration agreements, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.
CONTACT INFORMATION
Therapeutic Solutions International, Inc. ir@tsoimail.com
Corporate Communications:
NetworkWire (NW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkWire.com
Source: Therapeutic Solutions International, Inc.
© 2019 GlobeNewswire, Inc.
Back to News Headlines
Other Financial Information
Recent News & Disclosure Filings
Recent SEC Filings
Pink Current Information
Transfer Agent Verified
DAILY ADVANCERS
SRUXY
+ 50.79 %
NTGSF
+ 38.20 %
TFECY
+ 36.40 %
TFECF
+ 29.31 %
LVCLY
+ 20.00 %
Subscribe to Our Newsletter
Stay up to date on the latest company news, industry trends and regulatory changes that affect our markets and learn about members of our community.
Enter your email
SIGN UP
OCEANSIDE, Calif., July 08, 2019 (GLOBE NEWSWIRE) -- via NetworkWire -- Therapeutic Solutions International, Inc., (OTC Markets: TSOI) announced today the development of a broccoli sprout extract containing the precursor glucoraphanin in a combined 200mg dose of NanoStilbene.
As previously announced, the same NanoStilbene that was administered to 12 patients with advanced solid cancers for three weeks is the base for this new product we are calling "NanoPSA." Daily treatment with 300mg of NanoStilbene caused reduction in serum levels of inflammatory markers TNF-alpha, IL-6, and CRP [1]. Additionally, NK cytotoxicity was augmented, suggesting that NanoStilbene may be a useful adjuvant to immunotherapy of cancer rescuing T-cell and NK cell activities. These same inflammatory molecules are involved in elevated levels of PSA.
Glucoraphanin, found primarily in broccoli, is another potent antioxidant like pterostilbene. The main purpose of antioxidants is to protect the cells in our body from damage caused by oxidative stress, namely free radicals, which are unstable compounds missing an electron. This free radical damage is also closely linked with inflammation because the body recognizes oxidative damage as a threat.
We know what the result is, a damaging cycle of oxidation: damage – immune cells – more damage. Increasing antioxidant potential in the body provides a solution by helping to prevent a lot of the oxidative damage in the first place.
Glucoraphanin, as we have produced it, is a precursor to our end product, which is another compound called sulforaphane. Glucoraphanin belongs to a category of compounds called glucosinolates which are naturally found in cruciferous vegetables. Glucosinolates are enzymatically converted into isothiocyanates, which are active in the body. This enzymatic conversion is performed by myrosinase, which is also found naturally in cruciferous vegetables. Myrosinase-like activity also occurs in our intestinal microflora, so if glucoraphanin is consumed by itself, our gut microflora will convert a portion of it to sulforaphane, a compound within the isothiocyanate group of organosulfur compounds.
"This is an extremely exciting development in our research with our end target compound being sulforaphane. Sulforaphane has been shown to significantly reduce PSA after 20 weeks of consuming broccoli sprout extract (BSE). There is little misunderstanding that inflammation causes gut dysbiosis, and since we are depending upon the microflora to hydrolyze the glucoraphanin into sulforaphane, it seems perfectly reasonable to want the gut in the best shape it can be in. We already know pterostilbene supplementation causes beneficial changes in microbiota composition, improved metabolic function, strengthened insulin sensitivity and induced anti-obesity effects and so we have blended the two into a single formulation, providing a clinically relevant amount of both actives. Our mission is to either up-regulate or down-regulate the immune system, and NanoPSA is another tool in the box to achieve our mission," said Timothy Dixon, president and CEO of Therapeutic Solutions International. "We hope to have this product available, which will come in capsule form, on the shelf very quickly."
[1] https://mynanostilbene.com/?page_id=137
About Therapeutic Solutions International, Inc. Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. Immune modulation refers to the ability to upregulate (make more active) or downregulate (make less active) one's immune system. The Company's corporate website is www.therapeuticsolutionsint.com and e-commerce at www.youcanordernow.com.
Safe Harbor Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our SEC filings. To the extent that statements in this press release are not strictly historical, including statements as to product launch timing, revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future collaboration agreements, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.
CONTACT INFORMATION
Therapeutic Solutions International, Inc. ir@tsoimail.com
Corporate Communications:
NetworkWire (NW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkWire.com
Source: Therapeutic Solutions International, Inc.
© 2019 GlobeNewswire, Inc.
Back to News Headlines
Other Financial Information
Recent News & Disclosure Filings
Recent SEC Filings
Pink Current Information
Transfer Agent Verified
DAILY ADVANCERS
SRUXY
+ 50.79 %
NTGSF
+ 38.20 %
TFECY
+ 36.40 %
TFECF
+ 29.31 %
LVCLY
+ 20.00 %
Subscribe to Our Newsletter
Stay up to date on the latest company news, industry trends and regulatory changes that affect our markets and learn about members of our community.
Enter your email
SIGN UP
(0)
(0)Scroll down for more posts ▼